Latest filing published 02 Oct 2026 for Edgewise Therapeutics, Inc..
Filing timeline
BuySaleInsider track record
Closed purchases
Based on 2 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Purchases by company
Since each purchase
- +72.8%Entry US$22.75 · Close 23 Oct 2026 US$39.31
- +147.3%Entry US$10.94 · Close at T+365 US$27.06
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Jonathan C. Fox: trading record in brief
Jonathan C. Fox discloses dealings in 3 companies, chiefly Eidos Therapeutics, Inc., Edgewise Therapeutics, Inc. and MyoKardia, Inc. The record holds 53 filings, for trades running from 3 November 2015 to 1 October 2026.
Market trades split into 3 purchases (€291k) and 31 sales (€6.5M). Taken together, the sales exceed the purchases by €6.2M. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Outside the open market, there are 10 share grants.
The median purchase comes to €92k.
The newest entry dates from 2 October 2026: a share grant, in Edgewise Therapeutics, Inc. The clock since the last published purchase (13 November 2025) now reads 360 days. Typically, a trade is published a median of 2 days after it takes place. Section 16 rules allow two business days to file each Form 4. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Companies and markets linked to Jonathan C. Fox
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 308 shares0Common StockSEC:0001655016-26-000006:0
- 339 shares0Common StockSEC:0001655016-26-000002:0
- 473 shares0Common StockSEC:0001655016-26-000001:0
- 10,700 shares@ US$18.635865.3% of flowCommon StockSEC:0001655016-25-000007:0Canonical exit: 9 Feb 2026 (T+90)
- 728 shares0Common StockSEC:0001655016-25-000004:0
- 858 shares0Common StockSEC:0001562180-25-005233:0
- 559 shares0Common StockSEC:0001562180-25-002992:0
- 10,857 shares@ US$9.298934.7% of flowCommon StockSEC:0001562180-23-008573:0Canonical exit: 25 Mar 2024 (T+90)
- 500 shares0Common StockSEC:0000899243-21-003671:0
- 380,467 sharesCommon StockSEC:0000899243-21-003671:1
- 5,767 shares@ US$50.168.2% of flowCommon StockSEC:0000899243-20-025694:0
- 111 shares@ US$50.000.2% of flowCommon StockSEC:0000899243-20-025364:0
- 1,000 shares@ US$50.061.4% of flowCommon StockSEC:0000899243-20-025364:1
- 3,122 shares@ US$50.164.5% of flowCommon StockSEC:0000899243-20-025364:2
- 5,000 shares@ US$50.004.8% of flowCommon StockSEC:0000899243-20-018813:0
- 1,088 shares0Common StockSEC:0000899243-20-018110:0
- 444 shares@ US$41.570.3% of flowCommon StockSEC:0000899243-20-015413:0
- 5,000 shares@ US$50.004.3% of flowCommon StockSEC:0000899243-20-015413:3
- 1,020 shares0Common StockSEC:0000899243-20-015413:1
- 1,020 shares0Common StockSEC:0000899243-20-015413:2
- 5,000 shares@ US$50.004.4% of flowCommon StockSEC:0000899243-20-014714:0
- 2,847 shares@ US$50.002.3% of flowCommon StockSEC:0000899243-20-011341:0
- 2,153 shares@ US$50.001.7% of flowCommon StockSEC:0000899243-20-011341:1
- 10,000 shares@ US$51.577.9% of flowCommon StockSEC:0000899243-20-006941:0
- 10,000 shares@ US$54.008.1% of flowCommon StockSEC:0000899243-20-005000:1
25 of 53 declarations
